These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36209513)

  • 1. Botulinum toxin for Raynaud's phenomenon associated with systemic sclerosis: comment on the article by Senet et al.
    Yin H; Liu B; Li Q; Yan Q; Lu L
    Arthritis Rheumatol; 2023 Mar; 75(3):486. PubMed ID: 36209513
    [No Abstract]   [Full Text] [Related]  

  • 2. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D; Ahmad Z; Anderson MA; Johnson SR
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin injection for refractory Raynaud phenomenon and digital ulcers in systemic sclerosis.
    Shen YH; Lee YH; Leong PY
    Int J Rheum Dis; 2023 Feb; 26(2):187-189. PubMed ID: 36703271
    [No Abstract]   [Full Text] [Related]  

  • 5. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
    Nagarajan M; McArthur P
    Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a systematic review and meta-analysis.
    Elrosasy A; Abo Zeid M; Cadri S; Fahmy BM; Elzeftawy MA; Mohammed F; Ramadan A
    Arch Dermatol Res; 2024 Apr; 316(5):122. PubMed ID: 38630277
    [No Abstract]   [Full Text] [Related]  

  • 8. OnabotulinumtoxinA for Systemic Sclerosis-associated Raynaud's Phenomenon: A Multi-Institutional Study on Accessibility and Effectiveness.
    Kassamali B; Desai S; Min M; Mazori D; Villa-Ruiz C; Kus K; Cobos G; Merola J; LaChance A; Vleugels R
    J Drugs Dermatol; 2021 Nov; 20(11):1257-1259. PubMed ID: 34784129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review.
    Cai R; Yi Z; Li T; Mu R
    Chin Med J (Engl); 2022 May; 135(9):1133-1134. PubMed ID: 35773968
    [No Abstract]   [Full Text] [Related]  

  • 10. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
    Dhaliwal K; Griffin M; Denton CP; Butler PEM
    BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
    Uppal L; Dhaliwal K; Butler PE
    J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
    Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
    Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
    Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical Raynaud's phenomenon following iloprost infusion in a patient with systemic sclerosis.
    Bertelle D; Bertoldo E; Bixio R; Rossini M
    Scand J Rheumatol; 2023 Jan; 52(1):91-92. PubMed ID: 35723612
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
    J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's phenomenon: its relevance to scleroderma.
    Belch JJ
    Ann Rheum Dis; 1991 Nov; 50 Suppl 4(Suppl 4):839-45. PubMed ID: 1750795
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.